Survival in sentinel lymph node-positive pediatric melanoma

J Pediatr Surg. 2005 Jun;40(6):988-92; discussion 992. doi: 10.1016/j.jpedsurg.2005.03.014.

Abstract

Background: Sentinel lymph node (SLN) status is the strongest predictor of survival in adult melanoma. However, the prognostic value of SLN status in children and adolescents with melanoma is unknown.

Methods: Records of 327 patients aged 12 to 86 years undergoing SLN biopsy for melanoma or other melanocytic lesions were reviewed. A literature search identified additional patients younger than 21 years undergoing SLN biopsy for the same indications and these patients were combined with our series for meta-analysis.

Results: Sentinel lymph node metastases were found in 8 (40%) of 20 patients aged 12 to 20 years compared with 55 (18%) of 307 adults (P < .05). Median follow-up was 35 and 17 months for the groups, respectively. Sentinel lymph node-positive pediatric patients did not recur, whereas 14 (25%) adults recurred within this period. Of the 55 adults, 5 (9.1%) have died of disease. Of the combined SLN-positive children and adolescents from the literature (total n = 25), only a single (4%) child recurred at 6 months. The difference in survival for adult and pediatric patients was significant.

Conclusion: Pediatric patients have a higher incidence of SLN metastases than adults yet have a lower incidence of recurrence. Sentinel lymph node status does not predict early recurrence in pediatric patients with melanoma or atypical Spitz nevi.

Publication types

  • Comparative Study
  • Meta-Analysis

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Child
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphatic Metastasis
  • Male
  • Melanoma / pathology*
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Nevus, Epithelioid and Spindle Cell / pathology*
  • Prognosis
  • Retrospective Studies
  • Sentinel Lymph Node Biopsy*
  • Skin Neoplasms / pathology*